Orthofix Medical Inc. (OFIX) key performance indicators and operating metrics (15 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Gross Margin (Non-GAAP Pro Forma Adjusted) | 70.70 percent | FY2026-Q1 |
| Non-GAAP Pro Forma Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization Margin | 4.90 percent | FY2026-Q1 |
| Global Limb Reconstruction Net Sales | 32.80 | FY2026-Q1 |
| Net Sales - Bone Growth Therapies | 68.3M | FY2025-Q4 |
| Global Spine Net Sales | 180.6M | FY2025-Q4 |
| Free Cash Flow | 16.8M | FY2025-Q4 |
| Non-GAAP Pro Forma Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization | 29.2M | FY2025-Q4 |
| Net Sales - Global Orthopedics | 33.6M | FY2025-Q3 |
| Pro Forma Net Sales Excluding M6 Product Lines | 203.4M | FY2025-Q3 |
| Global Orthopedics Constant Currency Net Sales Growth | 6.00 percent | FY2025-Q3 |
| Procedure Volume Growth (United States Spine Fixation 1) | 10.00 percent | FY2025-Q3 |
| United States Orthopedics Net Sales Growth | 19.00 percent | FY2025-Q3 |
| United States Spine Fixation 1 Net Sales Growth | 8.00 percent | FY2025-Q3 |
| Non-GAAP Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization | 23.9M | FY2024-Q4 |
Back to OFIX overview · OFIX earnings · OFIX holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.